Pegaspargase
From Wikipedia, the free encyclopedia
|
Pegaspargase
|
|
| Systematic (IUPAC) name | |
| Pegylated E. coli L-asparagine amidohydrolase | |
| Identifiers | |
| CAS number | |
| ATC code | L01 |
| PubChem | ? |
| DrugBank | |
| Chemical data | |
| Formula | C1377H2208N382O442S17 |
| Mol. mass | 31731.9 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Pegaspargase is an antineoplastic agent.
It is used in the treatment of acute lymphoblastic leukemia.[1]
It is a form of L-asparaginase[2] which has undergone PEGylation.
[edit] References
- ^ Graham ML (2003). "Pegaspargase: a review of clinical studies". Adv. Drug Deliv. Rev. 55 (10): 1293–302. PMID 14499708.
- ^ UNM Cancer Center. Retrieved on 2007-08-28.

